SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Life Sciences gains as its arm signs drug discovery agreement with Orion Corporation

13 May 2014 Evaluate

Jubilant Life Sciences is currently trading at Rs 170.00, up by 1.55 points or 0.92% from its previous closing of Rs 168.45 on the BSE.

The scrip opened at Rs 170.45 and has touched a high and low of Rs 174.40 and Rs 168.00 respectively. So far 70115 shares were traded on the counter.

The BSE group 'B' stock of face value Rs 1 has touched a 52 week high of Rs 180.70 on 09-May-2014 and a 52 week low of Rs 65.10 on 28-Aug-2013.

Last one week high and low of the scrip stood at Rs 180.70 and Rs 151.00 respectively. The current market cap of the company is Rs 2705.39 crore.

The promoters holding in the company stood at 54.02% while Institutions and Non-Institutions held 26.82% and 19.15% respectively.

In a bid to develop medicines in the neuroscience therapeutic area, Jubilant Life Sciences has entered into drug discovery pact with Finland’s Orion Corporation. The company has entered into the agreement through its Bengaluru-based subsidiary Jubilant Biosys. The research deal is aimed at developing drug that can benefit large population with unmet needs in the pain management area.

Under the royalty-based alliance, Orion will provide royalty to Jubilant and will retain ownership of the compounds developed under the collaboration with exclusive worldwide rights, while Jubilant will offer integrated drug discovery services across synthetic and medicinal chemistry including scale up and pre-clinical facilities.

Jubilant Life Sciences is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.

Jubilant Pharmova Share Price

905.65 13.45 (1.51%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×